l-739594 and HIV-Infections

l-739594 has been researched along with HIV-Infections* in 2 studies

Reviews

2 review(s) available for l-739594 and HIV-Infections

Article	Year
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease. Journal of medicinal chemistry, 2009, Apr-23, Volume: 52, Issue:8 Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antiviral Agents; Aspartic Acid Endopeptidases; Biological Products; Darunavir; Drug Design; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Mimicry; Molecular Structure; Peptides; Structure-Activity Relationship; Sulfonamides	2009
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Our structure-based design strategies which specifically target the HIV-1 protease backbone, resulted in a number of exceedingly potent nonpeptidyl inhibitors. One of these inhibitors, darunavir (TMC114), contains a privileged, structure-based designed high-affinity P2 ligand, 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF). Darunavir has recently been approved for the treatment of HIV/AIDS patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens. Topics: Clinical Trials as Topic; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Structure; Structure-Activity Relationship; Sulfonamides	2007

Article

Year

Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.

Journal of medicinal chemistry, 2009, Apr-23, Volume: 52, Issue:8

Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antiviral Agents; Aspartic Acid Endopeptidases; Biological Products; Darunavir; Drug Design; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Mimicry; Molecular Structure; Peptides; Structure-Activity Relationship; Sulfonamides

2009

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

Our structure-based design strategies which specifically target the HIV-1 protease backbone, resulted in a number of exceedingly potent nonpeptidyl inhibitors. One of these inhibitors, darunavir (TMC114), contains a privileged, structure-based designed high-affinity P2 ligand, 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF). Darunavir has recently been approved for the treatment of HIV/AIDS patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens.

Topics: Clinical Trials as Topic; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Structure; Structure-Activity Relationship; Sulfonamides

2007